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Langerhans cells play a role in cell-mediated immune 
reactions which are often depressed in sarcoidosis. We 
examined the epidermis of 17 anergic patients with sar-
coidosis (Kveim-reactive and/or biopsy-proved) for the 
number of Langerhans cells in noninvolved skin and in 
any cutaneous sarcoidal lesions. Skin biopsies of 10 
healthy volunteers served as controls. In comparison to 
controls, the epidermis overlying noninvolved (p < 0.05), 
sarcoidal (p < 0.0005), and Kveim-reactive (p < 0.005) 
skin contained significantly fewer detectable Ia and T6 
antigen-bearing Langer hans cells. The reductions within 
noninvolved skin were most pronounced in patients with 
multisystem disease. Lower epidermal Langerhans cell 
densities, in comparison to controls, were detected in 
both prednisone-treated and untreated patients. Epider-
mis overlying sarcoidal skin of untreated patients con-
tained significantly fewer Ia and T6 antigen-bearing 
Langerhans cells (p < 0.05,p < 0.0025, respectively) than 
epidermis from noninvolved skin. Whether reduced 
numbers of cutaneous Langer hans cells are due to either 
a local and/ or systemic effect of sarcoidosis, or reflect 
the anergic state of these patients is unknown. 
Sarcoidosis is a systemic disease of unknown etiology in 
which cell-mediated immunity is often depressed [1)- Reduced 
delayed type hypersensitivity in these patients can be detected 
by hyporeactivity to a wide variety of bacterial, fungal, and 
viral antigens when skin-tested [2)- Whereas 90-95% of healthy 
controls exhibit a positive intradermal skin test to Candida 
albicans extract, positive reactions occur in only 40-53% of 
sarcoidosis patients [3,4)- Further evidence of depressed cell-
mediated immunity in the patients include reduction in the 
proliferative response of blood mononuclear cells to antigens 
and mitogens, and lower absolute numbers of peripheral blood 
T lymphocytes [5-7)- On the other hand, there is evidence that 
the depression in cell-mediated immunity is not absolute [8], in 
that sarcoidal disease does not delay the rejection of skin 
homografts [9], and increased numbers of "helper" T lympho-
cytes are localized within sarcoidal granulomas [10]. 
Although the origin and function of Langerhans cells has 
been a matter of conjecture and theory ever since their discov-
ery by Paul Langerhans [ll], similarities between Langerhans 
cells and macrophages recently have been reported. These 
similarities include plasma membrane 5'-adenosine triphospha-
tase (ATPase) activity [12], ability to migrate [13], !a-histocom-
patibility antigens [14,15], Fe receptors [16], C3b receptors 
[17], nonspecific esterase activity [18], the ability in vitro to 
transfer antigen in lymphocyte stimulation [19], and bone mar-
row derivation [20]. The finding that the Langerhans cells of 
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nonsensitized guinea pigs selectively bind certain common con-
tact allergens led Shelley and Juhlin to coin the term "reticulo-
epithelial system" for these cells, a system which traps and 
processes external contact allergens. Langerhans cells are im-
munocompetent cells playing a pivotal role in cell-mediated 
hypersensitivity reactions and in the pathogenesis of skin dis-
ease [21)-
lmmunofluorescent detection of cells expressing Ia and/or 
T6 antigenicity has been used to specifically enumerate Lan-
gerhans cells within normal epidermis [22,23]- We investigated 
17 anergic patients with sarcoidosis to determine (1) whether 
within the epidermis, the density of Langerhans cells (as de-
tected by Ia and T6 antigenicity) in noninvolved, sarcoidal, and 
Kveim-reactive skin differs from that within the epidermis of 
healthy volunteers, and (2) whether demographic and clinical 
features of these patients can be related to Langerhans cell 
density. 
PATIENTS 
Seventeen of 18 consecutive patients in attendance at the Sarcoidosis 
Clinic of the Mount Sinai Medical Center considered for inclusion in 
this study qualified, with the 1 pregnant patient being excluded. None 
of the 17 patients had received immunosuppressive medications other 
than glucocorticosteroids (6/17) and none had applied topical steroids 
for at least 6 months. All 17 patients had clinical features of sarcoidosis 
and histologic evidence of either a noncaseating granulomatous Kveim 
test (15/16) or a positive tissue biopsy with noncaseating epithelioid 
granulomas with little or no necrosis (9/10). Other causes of nonca-
seating granuloma formation were excluded. 
Demographic analysis of these patients revealed a population similar 
to that of a previous study conducted at this clinic (Table I) (24]. Ten 
healthly females having an average age of 52.8 years (range 36-65) 
served as control subjects. The Langerhans cell densities of the skin of 
this control group (see Results) were similar to those of20 other control 
subjects in another study (submitted for publication) in which no 
significant race, age, or sex differences in Langerhans cell densities were 
detected. 
Thirty-five percent (6/17) of the sarcoidosis patients were receiving 
oral prednisone; 1 patient was receiving 60 mg per day and the others 
7.5-10 mg per day. Four of the 6 patients were being treated with 
prednisone for more than 1 year. Five of the 17 sarcoidosis patients 
(29%) had sarcoidal skin lesions. All 17 patients were found to be 
anergic to intracutaneously injected Candidin extract. 
MATERIALS AND METHODS 
Shin Samples 
Following receipt of written informed consent, 4-mm punch biopsies 
were performed under 1% lidocaine local anesthesia. Twenty-four biop-
sies were obtained from the 17 patients and 10 fTom the control subjects. 
Biopsies were taken of "noninvolved skin" (non-sunexposed medical 
asf)ect of the right upper arm, n = 14), "sarcoidal skin" (cutaneous 
sarcoidosis of extremities, n = 5), clinically "Kveim-reactive skin" 
(flexor of right forearm, n = 5), and control skin (arm, n = 10). Light 
microscopic examination of clinically noninvolved skin samples failed 
to reveal any granulomas. 
Kveim Test 
Kveim antigen was prepared, testing was carried out, and cutaneous 
reactions histologically analyzed as previously described [1,25]. 
Immunofluorescent Detection of Epidermal Langerhans Cells 
The following antibodies were obtained commercially: monoclonal 
mouse antihuman T6 antigen IgG 1 (50 mg/ml; Ortho Pharmaceuticals, 
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TABLE I. Demographics and disease duration of sarcoidosis 
patients" 
R ace 
Black 59% 
Caucasoid 25% 
Hispanic 16% 
Sex 
Female 71% 
Male 29% 
Years of age 
22-49 71% 
50-76 29% 
Disease duration 
..;; 2 years 53% 
> 2 years 47% 
" Seventeen sarcoidosis patients anergic to Candidin. 
Raritan, New J ersey), monoclonal mouse ant ihuman Ia ant igen IgG2o. 
(1 mg/ ml; New England Nucleru·, Boston, Massachusetts), and goat 
antimouse IgG IgG fluorescein isothiocyanate (FITC) (F/ P = 4.7; 
Meloy Laboratories, Springfield, Virginia). Phosphate-buffered saline 
(PBS) was used for aU dilutions and washings. 
All samples were processed within 3 h following biopsy. Sepru·ation 
of e pidermis from dennis was carried out in 2 N NaBr at 37°C for 30 
min. Epidermal blisters were removed intact with fine forceps and 
bisected. Half of each blister was bathed in 50 1-11 of either monoclonal 
mouse antihuman Ia IgG2o. (1:100 dilution) or antihuman T6 IgG, (1:100 
dilution) at 37°C for 1 h. Following 3 10-min washings at 20°C, the 
samples were incubated in 50 1-11 of rabbi t antimouse IgG IgG-FITC 
(1:20 dilution) at 37°C for 1 h and washed 3 times. The samples were 
t hen mounted between 2 glass coverslips with glycerol gelatin and 
examined wi th epifluorescence microscopy and the fluorescing dendritic 
cells enumerated in at least 10 randomly chosen fields by an examiner 
who was unaware of the source of the specimen. The density of 
epidermal Langerhans cells is expressed as the mean number ± SEM 
per 0.1 mm2 • 
Statistics 
The mean number ± SEM of Langerhans cells within the epidermis 
of p atient and cont rol groups was determined. Compru·isons of the 
mean epidermal Langerhans cell densities of patient and control groups 
were performed using Student's I.-test with p values less than 0.05 
con s idered to be significant. 
RESULTS 
Comparison of the Number of Langerhans Cells Within 
Epidermis Overlying Noninuolued, Sarcoidal, Kueim-
Reactiue, and Control Shin 
The mean numbers of Ia and T6 antigen-bearing Langer hans 
cells per 0.1 mm2 within the epidermis overlying noninvolved 
skin of 17 sarcoidosis patients (14.1 ± 1.8, 31.5 ± 3.4, respec-
tively) were significantly (p < 0.05) less than those within 
control epidermis (18.3 ± 1.1, 39.5 ± 1.3, respectively). As shown 
in Fig 1, epidermis overlying sar coidal skin contained signifi-
cantly fewer Ia (6.7 ± 0.8) and T6 (16.3 ± 3.7) antigen-bearing 
cells when compared to either control epidermis (p < 0.025). 
Similarly, epidermis overlying Kveim-reactive skin contained 
fewer la (7.4 ± 1.2) and T6 (20.3 ± 9.0) antigen-bearing cells 
when compared to either control epidermis (p < 0.0005, p < 
0 .005, respectively ) or to the epidermis overlying noninvolved 
skin (p < 0.025, p < 0.10, respectively) . Although, in patients 
with sarcoidal skin the epidermis overly ing noninvolved skin 
contained only 83% (12.1 ± 1.1) of t he Ia and 78% (29.0 ± 7.3) 
of the T6-bearing Langerhans cells present in the epidermis 
overlying noninvolved skin of sarcoidosis patien ts without sar-
coidal skin lesions, these differences wer e not s ignificant. 
Comparison of the Number of Epidermal Langerhans Cells 
of Steroid- Treated and Untreated Sarcoidosis Patients 
As shown in Table II, the epidermis overly ing either nonin-
volved or sarcoidal skin for both steroid-treated and untreated 
patients contained significantly fewer Langerha ns cells than 
control epidermis. However, there are no significant differences 
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in the dens ities of epidermal Langerhans cells of prednisone-
treated and untreated patients. Furthermore, among untreated 
sarcoidosis patients epidermis overlying sarcoidal skin con-
tained fewer Ia and T6 antigen-bearing Langerhans cells (p < 
0.05, p < 0.0025, respectively) t han epidermis overlying nonin-
volved skin. 
Comparison of Epidermal Langerhans Cells in Patients with 
Both Noninuolued and Sarcoidal Shin 
Three patie n ts underwent biopsies of both noninvolved and 
sar coidal skin. As shown in Table III, the epidermis overlying 
sarcoidal skin in each case contained fewer Ia a nd T6 antigen-
bearing Langerh a ns cells t han t he epidermis overlying t h e ir 
noninvolved skin. 
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FIG 1. Density of Ia and T6 a ntigen-beru·ing Langerhans cells within 
noninvolved, sru·coidal, Kveim-reactive, and control skin. 
TABLE II. Density of epidermal Langerhans cells in sarcoidosis 
patients compared to controls" 
Epidermal Langerhans cells/ 0.1 mm2 (S0) 1' 
Subjects/ Source of Ia positive TG positive 
epidermis 
Untreated ' Steroid Untreated Steroid treated (' treated 
Sru·coid patients/ 12.7 (1.8)c 11.3 (1.4) 29.5 (2.8) 29.7 (3.9) 
Noninvolved p < 0.01 p < 0.0005 p < 0.0025 p < 0.01 
skin n =8 n= 6 n =S n =6 
Sru·coid patients/ 5.6 (0.8) 8.3 (0.4) 10.8 (0.0) 19.0 (9.1) 
Sru·coidal skin p < 0.0005 p < 0.0025 p < 0.0005 p < 0.0005 
n= 3 n= 2 n =3 n =2 
Healthy cont rols/ 18.3 (1.1) 39.5 (1.3) 
Normal skin n = 10 n = 10 
" Four-millimeter skin biopsies were obtained from 17 sarcoidosis 
patients and 10 healthy controls. 
I> Epidermal sheets separated from dermis by 2 N NaBr were incu-
bated in monoclonal mouse antihuman Ia or T6 IgG followed by rabbit 
antimouse IgG IgG-FITC. Ia and T6 antigen-bearing cells were enu-
merated under epifluorescence microscopy. 
c Patients not having received immunosuppressive therapy within 2 
years. 
"Patients present ly receiving oral prednisone (7.5-60 mg) for at least 
3 months. 
• p values refer to t-test comparisons of Langerhans cell densities in 
healthy controls (n = 10) and in the indicated subgroups of sru·coidosis 
patients. 
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TABLE III. Comparison of number of epidermal Langerhans cells 
within sarcoida.l and noninvolued shin of the same patient" 
Epidermal Langerhans cells/0.1 nun2 (SO) 1' 
Palienl Ia positive T 6 positive 
Noninvolved Sarcoid a! Non involved Sarcoidal 
skin skin skin skin 
1 9.9 (0.9) 4.6 (0.6) 15.0 (1.5) 10.7 (0.9) 
2 13.9 (1.4) 8.8 (1.1) 39.2 (2.0) 28.1 (1.0) 
3 12.7 (0.5) 7.9 (0.8) 32.8 (0.5) 9.9 (0.7) 
"Four-millimeter punch biopsies of both noninvolved and sarcoidal 
skin were obtained from 3 sarcoidosis patients. 
• Epidermal sheets separated from dermis by 2 N NaBr were incu-
bated in monoclonal mouse antihuman Ia or T6 IgG followed by rabbit 
antimouse IgG IgG-FITC. Ia and T6 antigen-bea1·ing cells were enu-
merated under epifluorescence microscopy. 
Epidermal Langerhans Cell Morphology 
We did not detect any consistent differences in either the 
dendritic nature or fluorescent staining intensity of either !a-
or T6-bearing Langerhans cells within epidermis overlying non-
involved, sarcoidal, Kveim-reactive, or control skin. 
Correlation of Demographic and Clinical Characteristics 
with the Number of Epidermal Langerhans Cells in 
Sarcoidosis Patients 
T he patients with the following clinical characteristics, there 
were no significant differences in the number of epidermal 
Langerhans cells in their noninvolved skin: age, < 50/~ 50 
years; sex, male/female; race, black/ Hispanic/Caucasian; radio-
graphic staging of disease, stage 1/stages 2 and 3; leukocyte 
count per mm3, < 4800/~ 4800; elevated lysozyme level,> 13 
J.tg/ < 13 j.tg; elevated erythrocyte sedimentation rate per h, > 
20 mm/< 20 mm; and elevated angiotensin converting enzyme 
per nmol min- 1, > 30/=s 30. However, patients with recent onset 
of sru·coidosis (=:; 2 years, "acute-subacute") tended (p < 0.15) 
to have more !a-bearing Langerhans cells in the epidermis of 
their nonin"volved skin (17.9 ± 4.2) than patients with "chronic" 
(> 2 years) disease (12.0 ± 2.0). Patients with biopsy-proved 
involvement of at least one organ system, other than lymph 
nodes, in addition to lung had significantly fewer !a-bearing 
Langerhans cells ( p < 0.05) in the epidermis of their nonin-
volved skin (10.5 ± 1.4) than patients with only lung involve-
ment (16.8 ± 2.6) with or without lymph node involvement. 
DISCUSSION 
The epidermis of patients with psoriasis [26], hyperkeratotic 
venucae [27], and contact dermatitis [28,29] has been reported 
to contain fewer Langerhans cells than present in control skin. 
In this study, we have found the density of epidermal Langer-
hans cells within the skin of sarcoidosis patients to be signifi-
cantly lower than within the skin of healthy volunteers. The 
reasons for the observed reductions are unclear. It is possible 
that the fewer numbers of Langerhans cells in these anergic 
patients reflect a systemic reduction in cell-mediated immunity, 
which has been suggested to occur in these patients [1,2,9,30]. 
Langerhans cells play a pivotal role in antigen presentation in 
contact sensitization, which has been reported to be reduced in 
patients with sarcoidosis [31]. 
The lower densities of epidermal Langerhans cells appear to 
parallel both the duration and extent of systemic sarcoidal 
involvement. Furthermore, the concept of systemic reductions 
in Langerhans cells is consistent with the recent finding of no 
Langerhans cells within alveolar epithelium of 41 sarcoidosis 
patients, while their presence was detected in normal and 
fibrotic lungs [32]. Local reductions in the number of epidermal 
Langerhans cells have been reported in other diseases [26-29] 
and after exposure to certain agents (33-35). In addition to a 
general reduction in epidermal Langerhans cells as compared 
to control skin, our finding of even lower densit ies of Langer hans 
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cells within epidermis overlying sarcoidal and Kveim-reactive 
skin than within that overlying noninvolved skin points to more 
localized reductions in areas of active disease. It is unknown 
whether these changes are due to the simple obstruction [36] 
to Langerhans cell migration to the epidermis or to the recruit-
ment of Langerhans cells within dermal inflltrates [37]. 
Systemic or epicutaneous exposure to glucocorticosteroids 
has been reported to induce dose-dependent reductions in the 
density of epidermal Langerhans cells [38-42]. Densities of 
epidermal Langerhans cells were observed in both steroid-
treated and untreated sarcoidosis patients to be less t han in 
controls. Yet, parallel reductions were found in both the steroid-
treated and untreated groups of patients and no significant 
differences were noted between the groups. These findings 
suggest that the lowered densit ies of Langerhans cells in these 
patients were not secondary to a steroid effect. The most 
probable explanation for the lack of a more pronounced reduc-
tion of Langer hans cells in the steroid-treated group is that 5 of 
these 6 patients were receiving low systemic doses of prednisone 
(7 .5-10 mg per day). Interestingly, the noninvolved skin of the 
1 patient receiving 60 mg prednisone daily, had the lowest 
density (4.2/0.1 mm2) of !a-bearing epiderma l Langerha ns cells 
of all patients tested. 
It has been our experience t hat the immunoflu orescent assay 
for Langerhans cell Ia expression detects 55-60% of the number 
of Langerhans cells determined by immunofluorescent detec-
tion of human T6 ant igen [ 41,42]. One could speculate that 
these assays differ in their ability to detect 2 different subpop-
ulations of Langerhans cells, indeterminate Langerhans cells, 
which have been suggested to be an immature form, and Bir-
beck granule cell-containing Langerhans cells. T6 antigens are 
expressed by all Langerhans cells [23] and the possibility exists 
that the expression of Ia ant igens, Fe, and C3b receptors ru·e 
restricted to differentiated Langerhans cells. Differences in 
assay sensitivities as the basis for the differences in Langerhans 
cell detection cannot be ruled out. 
In conclusion, we have found the density of epidermal Lan-
gerhans cells in sarcoidosis to be decreased; the degree to which 
t his is seen appears to pm·allel the disease chronicity and 
multisystem involvement. Whether these abnormal numbers of 
Langerhans cells are due to a local and/or a systemic effect of 
sarcoidosis, or reflect the anergic state of these patients is 
unknown. 
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Desmosomal Antigens Are Not Recognized by the Majority of Pemphigus 
Autoimmune Sera 
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Sera from 7 patients with pemphigus vulgaris and both 
mouse and rabbit antisera against bovine epidermal des-
mosomes contained antibodies that bound to cell surface 
components of the spinous layer of bovine epidermis. 
The antidesmosomal sera showed significant binding to 
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purified desmosomal proteins in an enzyme-linked im-
munosorbent assay (ELISA). Two of 7 pemphigus sera 
bowid to desmosomal protein-coated microtiter plates 
at low dilution titers. Two of 6 normal human sera also 
bound to desmosomal protein-coated microtiter plates 
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The University of Wisconsin-Madison, 1607 Observatory Drive, Mad-
ison, Wisconsin 53706. 
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BSA: bovine serum albumin 
ELISA: enzyme-linked immunosorbent assay 
PBS: phosphate-buffered saline 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis 
